<?xml version='1.0' encoding='utf-8'?>
<document id="31770456"><sentence text="Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours." /><sentence text="In vitro data show that talazoparib is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein transporters"><entity charOffset="24-35" id="DDI-PubMed.31770456.s2.e0" text="talazoparib" /></sentence><sentence text=" This open-label, 2-arm, drug-drug interaction Phase 1 study in patients with advanced solid tumours assessed the effect of a P-gp inhibitor (itraconazole) and a P-gp inducer (rifampicin) on the pharmacokinetics of a single dose of talazoparib"><entity charOffset="142-154" id="DDI-PubMed.31770456.s3.e0" text="itraconazole" /><entity charOffset="176-186" id="DDI-PubMed.31770456.s3.e1" text="rifampicin" /><entity charOffset="232-243" id="DDI-PubMed.31770456.s3.e2" text="talazoparib" /><pair ddi="false" e1="DDI-PubMed.31770456.s3.e0" e2="DDI-PubMed.31770456.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31770456.s3.e0" e2="DDI-PubMed.31770456.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31770456.s3.e0" e2="DDI-PubMed.31770456.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31770456.s3.e1" e2="DDI-PubMed.31770456.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31770456.s3.e1" e2="DDI-PubMed.31770456.s3.e2" /></sentence><sentence text=" The safety and tolerability of a single dose of talazoparib with and without itraconazole or rifampicin were also assessed"><entity charOffset="49-60" id="DDI-PubMed.31770456.s4.e0" text="talazoparib" /><entity charOffset="78-90" id="DDI-PubMed.31770456.s4.e1" text="itraconazole" /><entity charOffset="94-104" id="DDI-PubMed.31770456.s4.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.31770456.s4.e0" e2="DDI-PubMed.31770456.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31770456.s4.e0" e2="DDI-PubMed.31770456.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31770456.s4.e0" e2="DDI-PubMed.31770456.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31770456.s4.e1" e2="DDI-PubMed.31770456.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31770456.s4.e1" e2="DDI-PubMed.31770456.s4.e2" /></sentence><sentence text="" /><sentence text="Thirty-six patients were enrolled (Arm A [itraconazole], n = 19; Arm B [rifampicin], n = 17)" /><sentence text=" Patients in both arms received 2 single oral doses of talazoparib (0"><entity charOffset="55-66" id="DDI-PubMed.31770456.s7.e0" text="talazoparib" /></sentence><sentence text="5 mg, Arm A; 1 mg, Arm B) alone and with multiple daily oral doses of itraconazole (Arm A) or rifampicin (Arm B)"><entity charOffset="70-82" id="DDI-PubMed.31770456.s8.e0" text="itraconazole" /><entity charOffset="94-104" id="DDI-PubMed.31770456.s8.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.31770456.s8.e0" e2="DDI-PubMed.31770456.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31770456.s8.e0" e2="DDI-PubMed.31770456.s8.e1" /></sentence><sentence text="" /><sentence text="Coadministration of itraconazole and talazoparib increased talazoparib area under the plasma concentration-time profile from time 0 extrapolated to infinity by ~56% and maximum observed plasma concentration by ~40% relative to talazoparib alone"><entity charOffset="20-32" id="DDI-PubMed.31770456.s10.e0" text="itraconazole" /><entity charOffset="37-48" id="DDI-PubMed.31770456.s10.e1" text="talazoparib" /><entity charOffset="59-70" id="DDI-PubMed.31770456.s10.e2" text="talazoparib" /><entity charOffset="227-238" id="DDI-PubMed.31770456.s10.e3" text="talazoparib" /><pair ddi="false" e1="DDI-PubMed.31770456.s10.e0" e2="DDI-PubMed.31770456.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31770456.s10.e0" e2="DDI-PubMed.31770456.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31770456.s10.e0" e2="DDI-PubMed.31770456.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31770456.s10.e0" e2="DDI-PubMed.31770456.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31770456.s10.e1" e2="DDI-PubMed.31770456.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31770456.s10.e1" e2="DDI-PubMed.31770456.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31770456.s10.e1" e2="DDI-PubMed.31770456.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31770456.s10.e2" e2="DDI-PubMed.31770456.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31770456.s10.e2" e2="DDI-PubMed.31770456.s10.e3" /></sentence><sentence text=" Coadministration of rifampicin and talazoparib increased talazoparib maximum observed plasma concentration by approximately 37% (geometric mean ratio 136"><entity charOffset="21-31" id="DDI-PubMed.31770456.s11.e0" text="rifampicin" /><entity charOffset="36-47" id="DDI-PubMed.31770456.s11.e1" text="talazoparib" /><pair ddi="false" e1="DDI-PubMed.31770456.s11.e0" e2="DDI-PubMed.31770456.s11.e0" /><pair ddi="false" e1="DDI-PubMed.31770456.s11.e0" e2="DDI-PubMed.31770456.s11.e1" /></sentence><sentence text="6% [90% confidence interval 103" /><sentence text="2-180" /><sentence text="9]); area under the curve was not affected relative to talazoparib alone (geometric mean ratio 102" /><sentence text="0% [90% confidence interval 94" /><sentence text="0-110" /><sentence text="7])" /><sentence text=" Talazoparib had an overall safety profile consistent with that observed in prior studies in which talazoparib was administered as a single dose"><entity charOffset="1-12" id="DDI-PubMed.31770456.s18.e0" text="Talazoparib" /><entity charOffset="99-110" id="DDI-PubMed.31770456.s18.e1" text="talazoparib" /><pair ddi="false" e1="DDI-PubMed.31770456.s18.e0" e2="DDI-PubMed.31770456.s18.e0" /><pair ddi="false" e1="DDI-PubMed.31770456.s18.e0" e2="DDI-PubMed.31770456.s18.e1" /></sentence><sentence text="" /><sentence text="Coadministration of itraconazole increased talazoparib plasma exposure compared to talazoparib alone"><entity charOffset="20-32" id="DDI-PubMed.31770456.s20.e0" text="itraconazole" /><entity charOffset="43-54" id="DDI-PubMed.31770456.s20.e1" text="talazoparib" /><entity charOffset="83-94" id="DDI-PubMed.31770456.s20.e2" text="talazoparib" /><pair ddi="false" e1="DDI-PubMed.31770456.s20.e0" e2="DDI-PubMed.31770456.s20.e0" /><pair ddi="false" e1="DDI-PubMed.31770456.s20.e0" e2="DDI-PubMed.31770456.s20.e1" /><pair ddi="false" e1="DDI-PubMed.31770456.s20.e0" e2="DDI-PubMed.31770456.s20.e2" /><pair ddi="false" e1="DDI-PubMed.31770456.s20.e1" e2="DDI-PubMed.31770456.s20.e1" /><pair ddi="false" e1="DDI-PubMed.31770456.s20.e1" e2="DDI-PubMed.31770456.s20.e2" /></sentence><sentence text=" A reduced talazoparib dose is recommended if coadministration of potent P-gp inhibitors cannot be avoided"><entity charOffset="11-22" id="DDI-PubMed.31770456.s21.e0" text="talazoparib" /></sentence><sentence text=" Similar exposure was observed when talazoparib was administered alone and with rifampicin suggesting that the effect of rifampicin on talazoparib exposure is limited"><entity charOffset="36-47" id="DDI-PubMed.31770456.s22.e0" text="talazoparib" /><entity charOffset="80-90" id="DDI-PubMed.31770456.s22.e1" text="rifampicin" /><entity charOffset="121-131" id="DDI-PubMed.31770456.s22.e2" text="rifampicin" /><entity charOffset="135-146" id="DDI-PubMed.31770456.s22.e3" text="talazoparib" /><pair ddi="false" e1="DDI-PubMed.31770456.s22.e0" e2="DDI-PubMed.31770456.s22.e0" /><pair ddi="false" e1="DDI-PubMed.31770456.s22.e0" e2="DDI-PubMed.31770456.s22.e1" /><pair ddi="false" e1="DDI-PubMed.31770456.s22.e0" e2="DDI-PubMed.31770456.s22.e2" /><pair ddi="false" e1="DDI-PubMed.31770456.s22.e0" e2="DDI-PubMed.31770456.s22.e3" /><pair ddi="false" e1="DDI-PubMed.31770456.s22.e1" e2="DDI-PubMed.31770456.s22.e1" /><pair ddi="false" e1="DDI-PubMed.31770456.s22.e1" e2="DDI-PubMed.31770456.s22.e2" /><pair ddi="false" e1="DDI-PubMed.31770456.s22.e1" e2="DDI-PubMed.31770456.s22.e3" /><pair ddi="false" e1="DDI-PubMed.31770456.s22.e2" e2="DDI-PubMed.31770456.s22.e2" /><pair ddi="false" e1="DDI-PubMed.31770456.s22.e2" e2="DDI-PubMed.31770456.s22.e3" /></sentence><sentence text="" /></document>